The Wall Street Journal reports on innovative approaches to getting people to enroll in clinical trials, including one that it describes as "a sort of medical matchmaker that is gaining wider usage: EmergingMed, a for-profit service that connects patients to cutting-edge clinical trials." Let's hope one of these programs works. While they may not realize it, consumers are an essential part of the biomedical enterprise and new treatments can't emerge without them.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.